Ignite Creation Date:
2025-12-25 @ 2:24 AM
Ignite Modification Date:
2025-12-28 @ 12:05 AM
Study NCT ID:
NCT06757634
Status:
RECRUITING
Last Update Posted:
2025-06-18
First Post:
2024-12-24
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Sponsor:
Celcuity Inc
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-06-30
Start Date Type:
ESTIMATED
Primary Completion Date:
2027-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-12-30
Completion Date Type:
ESTIMATED
First Submit Date:
2024-12-24
First Submit QC Date:
None
Study First Post Date:
2025-01-03
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-06-14
Last Update Post Date:
2025-06-18
Last Update Post Date Type:
ACTUAL